Pobitra Borah

805 total citations
19 papers, 429 citations indexed

About

Pobitra Borah is a scholar working on Molecular Biology, Infectious Diseases and Organic Chemistry. According to data from OpenAlex, Pobitra Borah has authored 19 papers receiving a total of 429 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Infectious Diseases and 4 papers in Organic Chemistry. Recurrent topics in Pobitra Borah's work include Tuberculosis Research and Epidemiology (4 papers), Computational Drug Discovery Methods (4 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). Pobitra Borah is often cited by papers focused on Tuberculosis Research and Epidemiology (4 papers), Computational Drug Discovery Methods (4 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). Pobitra Borah collaborates with scholars based in India, Jordan and Saudi Arabia. Pobitra Borah's co-authors include Pran Kishore Deb, Katharigatta N. Venugopala, Satyendra Deka, Nizar A. Al‐Shar’i, Vinayak Singh, Raghu Prasad Mailavaram, Vinod K. Tiwari, Wafa Hourani, Partha Pratim Dutta and Raja Chakraborty and has published in prestigious journals such as International Journal of Biological Macromolecules, Current Medicinal Chemistry and Current Pharmaceutical Design.

In The Last Decade

Pobitra Borah

18 papers receiving 416 citations

Peers

Countries citing papers authored by Pobitra Borah

Since Specialization

Citations

This map shows the geographic impact of Pobitra Borah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pobitra Borah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pobitra Borah more than expected).

Fields of papers citing papers by Pobitra Borah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pobitra Borah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pobitra Borah. The network helps show where Pobitra Borah may publish in the future.

Co-authorship network of co-authors of Pobitra Borah

This figure shows the co-authorship network connecting the top 25 collaborators of Pobitra Borah. A scholar is included among the top collaborators of Pobitra Borah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pobitra Borah. Pobitra Borah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Anticancer and Cyclooxygenase Inhibitory Activity of Benzylidene Derivatives of Fenobam and its Thio Analogues 2024 ·Current Medicinal Chemistry ·Wafa Hourani, Pran Kishore Deb, (unknown), Nizar A. Al‐Shar’i, Pobitra Borah, Lina A. Dahabiyeh, (unknown), (unknown), (unknown), Jagadeesh Prasad Dasappa, Katharigatta N. Venugopala	0
2	Identification of potent indolizine derivatives against Mycobacterial tuberculosis: In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies 2024 ·International Journal of Biological Macromolecules ·Katharigatta N. Venugopala, Sandeep Chandrashekharappa, Pran Kishore Deb, Nizar A. Al‐Shar’i, Melendhran Pillay, (unknown), Deepak Chopra, Pobitra Borah, (unknown), Lionel Mourey, Christian Lherbet, Bandar E. Al‐Dhubiab, Christophe Tratrat, Mahesh Attimarad, Anroop B. Nair, Nagaraja Sreeharsha, Raghu Prasad Mailavaram, Rashmi Venugopala, Viresh Mohanlall, Mohamed A. Morsy	7
3	Icacinaceae Plant Family: A Recapitulation of the Ethnobotanical, Phytochemical,Pharmacological, and Biotechnological Aspects 2023 ·Current Pharmaceutical Design ·(unknown), Pobitra Borah, Pran Kishore Deb, Katharigatta N. Venugopala, S Hemalatha	1
4	Recent approaches in the drug research and development of novel antimalarial drugs with new targets 2023 ·Acta Pharmaceutica ·(unknown), (unknown), (unknown), Pottathil Shinu, Pobitra Borah, Katharigatta N. Venugopala, Pran Kishore Deb, Raghu Prasad Mailavaram	8
5	Evolving spectrum of diabetic wound: Mechanistic insights and therapeutic targets 2022 ·World Journal of Diabetes ·Raja Chakraborty, Pobitra Borah, Partha Pratim Dutta, Saikat Sen	38
6	Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go? 2021 ·Human Vaccines & Immunotherapeutics ·Gaurav Joshi, Pobitra Borah, Shweta Thakur, Praveen Sharma, Mayank Mayank, Poduri Ramarao	18
7	ADMET Profiling in Drug Discovery and Development: Perspectives of In Silico, In Vitro and Integrated Approaches 2021 ·Current Drug Metabolism ·(unknown), Pobitra Borah, Pran Kishore Deb, Katharigatta N. Venugopala, Wafa Hourani, Muhammed Alzweiri, Sanaa K. Bardaweel, Vinod K. Tiwari	74
8	Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19 2021 ·Frontiers in Molecular Biosciences ·Rajashri Bezbaruah, Pobitra Borah, (unknown), Nizar A. Al‐Shar’i, Balakumar Chandrasekaran, Da’san M. M. Jaradat, Munir A. Al‐Zeer, Saeid Abu-Romman	20
9	Perspectives on RNA Vaccine Candidates for COVID-19 2021 ·Frontiers in Molecular Biosciences ·Pobitra Borah, Pran Kishore Deb, Nizar A. Al‐Shar’i, Lina A. Dahabiyeh, Katharigatta N. Venugopala, Vinayak Singh, Pottathil Shinu, Snawar Hussain, Satyendra Deka, Balakumar Chandrasekaran, Da’san M. M. Jaradat	40
10	In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies of substituted 1,2,4-oxadiazole analogues against Mycobacterium tuberculosis 2021 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Pran Kishore Deb, Nizar A. Al‐Shar’i, Katharigatta N. Venugopala, Melendhran Pillay, Pobitra Borah	38
11	Current Scenario and Future Prospect in the Management of COVID-19 2021 ·Current Medicinal Chemistry ·Pobitra Borah	1
12	Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted 2021 ·Frontiers in Molecular Biosciences ·Pobitra Borah, Pran Kishore Deb, Balakumar Chandrasekaran, Manoj Goyal, (unknown), Snawar Hussain, Pottathil Shinu, Katharigatta N. Venugopala, Nizar A. Al‐Shar’i, Satyendra Deka, Vinayak Singh	33
13	Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies 2020 ·Current Topics in Medicinal Chemistry ·Pobitra Borah, Pran Kishore Deb, Katharigatta N. Venugopala, Nizar A. Al‐Shar’i, Vinayak Singh, Satyendra Deka, (unknown), Vinod K. Tiwari, Raghu Prasad Mailavaram	30
14	Application of Advanced Technologies in Natural Product Research: A Review with Special Emphasis on ADMET Profiling 2020 ·Current Drug Metabolism ·Pobitra Borah, (unknown), Satyendra Deka, Katharigatta N. Venugopala, Anroop B. Nair, Mahesh Attimarad, Nagaraja Sreeharsha, Raghu Prasad Mailavaram	16
15	Current advances in the clinical development of anti-tubercular agents 2020 ·Tuberculosis ·(unknown), (unknown), Raghu Prasad Mailavaram, Vinayak Singh, Pobitra Borah, Pran Kishore Deb, Katharigatta N. Venugopala, Wafa Hourani, Rakesh Kumar Tekade	31
16	Anticancer Activity and In Silico ADMET Properties of 2,4,5-Trisubstitutedthiazole Derivatives 2020 ·Current Drug Metabolism ·(unknown), (unknown), Sanaa K. Bardaweel, Pran Kishore Deb, Pobitra Borah, Katharigatta N. Venugopala, (unknown), (unknown)	4
17	Current Scenario and Future Prospect in the Management of COVID-19 2020 ·Current Medicinal Chemistry ·Pobitra Borah, Pran Kishore Deb, Satyendra Deka, Katharigatta N. Venugopala, Vinayak Singh, Raghu Prasad Mailavaram, Kiran Kalia, Rakesh Kumar Tekade	19
18	P1 Receptor Agonists/Antagonists in Clinical Trials - Potential Drug Candidates of the Future 2019 ·Current Pharmaceutical Design ·Pobitra Borah, Satyendra Deka, Raghu Prasad Mailavaram, Pran Kishore Deb	14
19	Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives 2019 ·Current Pharmaceutical Design ·Pran Kishore Deb, Satyendra Deka, Pobitra Borah, Sara Nidal Abed, Karl‐Norbert Klotz	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact